Abstracts

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).

#	Title	Authors	Category	Keywords
O70	CD122-selective IL-2 complexes treat ovarian carcinomas, possibly by dysregulating Treg differentiation and reducing suppression, and promoting T cell stem cells	Yilun Deng, MD, PhD; Justin M. Drerup; Xinyue Zhang; Ryan M. Reyes; Jenny A. Mendez; Myrna G. Garcia; Alvaro S. Padron; Harshita B. Gupta, PhD; Tyler Curiel, MD;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
O71	AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells	Sterling C. Eckard, PhD; Leah N. Gehrs; Victoria Smith; Jeanmarie Guenot; John F. DiPersio; Sheng Wei, MD; Michael P. Rettig;	Novel Single-Agent Immunotherapies	Clinical trial; Immune suppression; Leukemia/Lymphoma; Myeloid cells; MDSC; Solid tumors; T cell; Targeted therapy
O72	Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers	Fan Zhang, PhD; Neha Parayath, PhD; Michael Coon, MS; Sirkka Stephan, PhD; Matthias Stephan, MD, PhD;	Novel Single-Agent Immunotherapies	Dendritic cell; Immune adjuvant; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P756	HER2-targeting TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR- dependent manner.	Shelley E. Ackerman, PhD; Joseph C. Gonzalez; Cecelia I. Pearson; Shelley E. Ackerman, PhD; Justin A. Kenkel; Po Y. Ho; Angela Luo; Murray N. Nguyen; Jason C. Paik, MD PhD; Arthur Lee; Richard P. Laura; Hai Li; Cindy Kreder; Karla A. Henning; Steve J. Chapin; Bruce H. Devens; Brian S. Safina; David Y. Jackson; Edgar Engleman; David Dornan, PhD; Michael N. Alonso;	Novel Single-Agent Immunotherapies	Antibody; Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens
P757	Novel SIRP antibodies with differentiated characteristics for targeting innate immunity in cancer	Gabriela Andrejeva, PhD; Benjamin J. Capoccia, PhD; Michael J. Donio, MS; Ronald R. Hiebsch, BS; Robyn J. Puro, PhD; Myriam N. Bouchlaka, PhD; Daniel S. Pereira, PhD;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Monocyte/Macrophage; Targeted therapy
P758	COBRA: A novel conditionally active bispecific antibody that regresses established solid tumors in mice	Anand Panchal; Andisheh Bagheri, MS; Maia Vinogradova; Tim Chen; Russell Wall; Stéphanie Levon; Pui Seto; Jessica Krakow; Brian Hillier; Ying Zhu; Danielle Dettling; Jeremiah Degenhardt; Aakash Datt; Eilene Kwok; Lucy Quach; Patricia A. Culp; Chad May; Bob DuBridge;	Novel Single-Agent Immunotherapies	Antibody; Antigen presenting cells; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment
P759	DZD2269, a novel A2AR antagonist capable of overcoming high adenosine induced immunosuppression	Yu Bai, M.Sc; Xin Zhang; Jie Zheng; Yingchun Wang; Lingli Zhang; Yu Bai, M.Sc; Yu Bai, M.Sc; Zhenfan Yang;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Chemotherapy; Cytokine; Immune suppression; Radiotherapy; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment
P760	Local modulation of T cell PD-1 using self-delivering RNAi as a potential immunotherapeutic	John A. Barrett, PhD; James Cardia; Melissa Maxwell; Mani D. Kadiyala, M.S>; Dingxue Yan, PhD; Winnie Tam; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
P761	Tumor-targeted bacterial nanocells carrying a super-cytotoxic drug elicit an anti-tumor immune response, long-term survival, prolonged tumor remission, and resistance to tumor re-challenge	Himanshu Brahmbhatt, PhD;	Novel Single-Agent Immunotherapies	Antigen presenting cells; Chemokine; Cytokine; Monocyte/Macrophage; NK/NK T cell; T cell; Targeted therapy; Tumor microenvironment
P762	Antibodies to ILT3 (LILRB4) abrogate myeloid immunosuppression and combine with PD1 blockade to enable T cell activation and function.	Philip E. Brandish, PhD; Jeanne Baker; Alan Byford; MIchael Caniga; Craig Chappell; Holly Cherwinski; Daniel J. Cua; Laurence Fayadat-dilman; Brian Hall; Barbara Joyce-Shaikh, BS.; Veronica Juan; Carl Mieczkowski; Anthony Palmieri; Yujie Qu, MD; Latika Singh; Peter Stiivers; Jie Zhang-Hoover;	Novel Single-Agent Immunotherapies	Antigen presenting cells; Dendritic cell; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor evasion
P763	Target Engagement and PK/PD quantification in humanized tumor model for anti-ILT3 mAb discovery	Alan J. Byford, MSc.; Yujie Qu, MD; Xiaoyan Du; Daping Zhang; Yvonne Yannoni; Laurence Fayadat-dilman; Brian Hall; Jeanne Baker; Michael Meehl; Scott Pruitt, MD, PhD; Lily Moy; Philip Brandish; Jie Zhang-Hoover;	Novel Single-Agent Immunotherapies	Biomarkers; Myeloid cells; Tumor infiltrating lymphocytes (TILs)
P764	Directly targeting FOXP3 with AZD8701, a first-in-class high affinity antisense oligonucleotide to relieve immunosuppression in cancer.	Larissa S. Carnevalli, PhD; Alexey Revenko; Charles So. Sinclair; Alison Peter; Molly A. Taylor; Anisha Solanki, PhD; Melissa Chapman; James Yates; Helen K. Angell, BSc PhD; Frederick Goldberg; Robert MacLeod; Larissa S. Carnevalli, PhD;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor evasion; Tumor microenvironment
P765	First in class antibody targeting Galectin-9 promotes anti-tumor response against pancreatic and other solid cancers	Linxiao Chen, PhD; Wei Wang, MD; Akiko Koide, PhD; Adrian Seifert, MD; Lena Seifert; Aleksandra Filipovic, MD, PhD; George Miller; Shohei Koide, PhD; Linxiao Chen, PhD;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P766	The distinct binding footprints of bispecific T cell receptors (TCR) and TCR-mimic antibodies underpin their altered pHLA selectivity	David K. Cole; Rory Crean; Johanne Pentier; Ben de Wet; Angharad Lloyd; Bent K. Jakobsen, PhD; Christopher Holland;	Novel Single-Agent Immunotherapies	Antibody; Immune toxicity; T cell; Targeted therapy; Tumor antigens
P767	Single-Cell Cytometry with the Genesis System - A scalable solution for high-parameter epitope detection	Jon Bell, BS, MS; Yad Deol, PhD, MS; Shaun Connor, BS, MBA; Tyler Burns, PhD;	Novel Single-Agent Immunotherapies	Antibody; B cell; Biomarkers; Immune monitoring; Myeloid cells; NK/NK T cell; T cell; Targeted therapy
P768	Antagonism of Signaling through the Vasoactive Intestinal Peptide Receptor as a Novel Immunotherapy in Preclinical Models of Melanoma.	Rohan K. Dhamsania, BS; Sruthi Ravindranathan, PhD; Shuhua Wang, MD; Rebecca A. Pankove, MS; David Francis; Susan N. Thomas, PhD, BS; Brian Pollack; Edmund K. Waller, MD, PhD, FACP;	Novel Single-Agent Immunotherapies	Adoptive immunotherapy; Checkpoint blockade; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
P769	Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in the mouse syngeneic MC38-OVA tumor model	Aatman S. Doshi, MS; Susan Cantin; Michael Secinaro; Yanjun Wang; Laura Prickett; Sharon Tentarelli; Scott Mlynarski; Eric Gangl; M. Raymond V. Finlay; Wenlin Shao, PhD; Alwin Schuller;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; Myeloid cells; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P770	A novel class of multi-specific antibodies targeting NKp30 on innate immune cells	Monia Draghi, PhD; Allison Nelson; Amanda Oliphant; Alan Leung; Jay Vekeria; Zach Frye; Claire Chottin; Sara Haserlat; Rachel Rennard; Caitlin Goshert; Rachel McCrory; Lucy Liu; Kenneth Rogers; Francois Villinger; Piotr Bobrowicz; Michael Schmidt; Jennifer Watkins-Yoon;	Novel Single-Agent Immunotherapies	NK/NK T cell
P771	An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs)	Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Justin M. David; M Maria Morelli, MD; Christina M. Annunzata, MD; Philip M. Arlen, MD;	Novel Single-Agent Immunotherapies	Antibody; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Targeted therapy; Tumor antigens
P772	Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor	Michael Khodadoust, MD PhD; Youn H. Kim, MD; Michael Yang; Heather Torrey, PhD; Lisa Tran; Denise L. Faustman, MD, PhD;	Novel Single-Agent Immunotherapies	Antibody; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell; Tumor microenvironment
P773	ONCR-177, an oncolytic HSV designed to safely and potently activate systemic anti-tumor immunity	Sonia Feau, Ph.D; Melissa Hayes; Brian Haines; Agnieska Denslow; Jacqueline Gursha; Daniel Wambua; Shreeya Khatiwada; Lingxin Kong; Jacob Spinale; Prajna Behera; Peter Grzesik; Jennifer s. Lee; Terry Farkaly; Edward m. Kennedy; Lorena Lerner; Christophe Queva;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Chemokine; Costimulation; Cytokine; Dendritic cell; Immune adjuvant; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens
P774	Intratumoral depletion of regulatory T cells using CD25 targeted photoimmunotherapy elicits anti-cancer immune activity and synergizes with PD1 checkpoint blockade in immunocompetent mouse models	Michelle A. Hsu; Stephanie M. Okamura; Daniele M. Bergeron; Estela Solis; Dany Gitnick; Roger Heim; Jerry Fong, PhD; Jerry Fong, PhD; Miguel Garcia-Guzman;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P775	Crosslink-Independent CD137 Agonism is Associated with Liver Inflammation	Miguel Gaspar, PhD; John Pravin; Leonor LR. Rodrigues, MSc; Alexander Koers, PhD; Mihriban Tuna, PhD; Neil Brewis, PhD;	Novel Single-Agent Immunotherapies	Antibody; Costimulation; Immune adjuvant; Immune toxicity; Inflammation; Regulatory T cell (Treg cell); T cell
P776	Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity	Laurent Gauthier, PhD; Ariane Morel, PhD; Nadia Anceriz; Benjamin Rossi; Audrey Blanchard-Alvarez; Gwendoline Grondin; Sylvia Trichard; Cédric Cesari; Melody Sapet; Frédéric Bosco; Hélène Rispaud-Blanc; Franceline Guillot; Stéphanie Cornen; Alain Roussel; Béatrice Amigues; Guillaume Habif; Flavien Caraguel; Sandrine Arrufat; Romain Remark, PhD; François Romagné; Yannis Morel, PhD; Eric Vivier;	Novel Single-Agent Immunotherapies	Antibody; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens
P777	Engineered monomeric JAG1 and multimeric DLL1 Notch ligand constructs enhance antitumor immunity by reducing exhaustion of T-effector memory cells	Uttam Laksmi Mounika Goruganthu, M Tech; Anil Shanker, PhD; David P. Carbone, MD, PhD; Elena Tchekneva, MD; Anneliese Antonucci; Michael Koenig; Longzhu Piao; Anwari Akhter, PhD; Parvathi Ranganathan; Nicholas Long; Thomas Magliery; Jason Evans; Rajeswara Arasada; Pierre P. Massion, MD; Mikhail M. Dikov, PhD; Roman V. Uzhachenko, PhD MD; Portia Thomas; Asel K. Biktasova, MD, PhD; Duafalia Dudimah; Maria Teresa P. De Aquino, PhD;	Novel Single-Agent Immunotherapies	Antigen presenting cells; Dendritic cell; Regulatory T cell (Treg cell); Solid tumors; Tumor evasion
P778	ATRC-101: A First-in-Class Engineered Fully Human Monoclonal Antibody that Targets a Tumor-Restricted Ribonucleoprotein Complex	Norman M. Greenberg, PhD; Jeffrey DeFalco, PhD; Daniel Emerling, PhD; Amy Manning-Bog, PhD; Gilson Baia, PhD; Shaun M. Lippow, PhD; Alexander Scholz, PhD; Yanhong Zhu, MD; Guy Cavet, PhD; Wayne Volkmuth, PhD; Ish Dhawan, PhD; Jonathan Benjamin, MD, PhD; William Robinson, MD PhD; Tito A. Serafini, PhD; Norman M. Greenberg, PhD;	Novel Single-Agent Immunotherapies	Antibody; B cell; Bioinformatics; Checkpoint blockade; Targeted therapy; Tumor antigens
P779	HER2/PD-L1/CD3/HSA tetra-specific antibody mediates cytolytic synapse-restricted PD-L1 blockade and potent depletion of HER2+ tumors	Tea Gunde, PhD; Alexandre Simonin; David Urech; Stefan Warmuth; Christian Hess; Matthias Brock; Eva Oswald; Julia Zeberer; Dania Diem; Dana Mahler; Diego Morenzoni; Simone Muntwiler; Benjamin Küttner; Robin Heiz; Naomi Flückiger; Sebastian Meyer; Timothy Egan;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Solid tumors; Targeted therapy
P780	Selection and in vitro characterization of ABBV-368, a novel anti-OX40 agonist antibody	Fiona Harding, PhD; Marcia Stickler; Margo Werner; Jennifer Tran; Nicole Belmar, BS; Archana Thakur; Enrico DiGiammarino; David Powers; Fiona Harding, PhD;	Novel Single-Agent Immunotherapies	Antibody; Costimulation; T cell
P781	A new approach used to characterise off target peptide repertoires for T cell receptors that target the cancer testis antigen NY-ESO-1-HLA-A*02:01	Stephen Harper; Charlotte H. Coles, PhD; Rachel M. Mulvaney; Sunir Malla, PhD; Andrew Walker, PhD; Kathrine J. Smith; Angharad Lloyd; Jane Harper; Zoe Donnelan; Andrew Knox; Andrea R. Stacey; Joseph Dukes; Emma Baston; Suzanne Griffin;	Novel Single-Agent Immunotherapies	T cell; Tumor antigens
P782	A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism	Kristen Hurov, PhD; Punit Upadhyaya; Marianna Kleyman; Jessica Kublin; Tom L. Stephen; Jun Ma; Elizabeth M. Repash; Julia Kristensson; Sophie Watcham; Liuhong Chen; Sailaja Battula, PhD; Johanna lahdenranta; Kevin McDonnell, PhD; Nicholas Keen;	Novel Single-Agent Immunotherapies	Costimulation; Cytokine; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment
P783	DuoBody®-CD3x5T4 shows potent preclinical anti-tumor activity in vitro and in vivo in a range of cancer indications	Kristel Kemper, PhD; Ellis Gielen; Laura Smits-de Vries; Sandra Verploegen; Mischa Houtkamp; Saskia Burm; Edward van den Brink; Rik Rademaker; Dennis Verzijl; Patrick Engelberts; Bart E.C.G. de Goeij; David Satijn; A. Kate Sasser; Esther Breij, PhD;	Novel Single-Agent Immunotherapies	Antibody; Biomarkers; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens
P784	SBT6050, a HER2-directed TLR8 agonist antibody conjugate, designed to overcome primary resistance to and synergize with checkpoint inhibition in HER2-expressing tumors	Kara Moyes; Jamie Brevik; Damion Winship; Ty Brender; Heather Metz; Yvette Latchman, PhD; Monica Childs; Michael Comeau; Jenny R. Chang; Sean W. Smith; Hengyu Xu; Ben Setter; Ray Carrillo; Li-Qun Fan; Phil Tan; Robert E. DuBose; Peter Baum; Valerie Odegard, PhD;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Dendritic cell; Myeloid cells; Solid tumors; T cell; Targeted therapy; TLR; Tumor antigens; Tumor microenvironment
P785	Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared to recombinant IL-12	Katherine Kirwin; Chang Ling Sia; Sonya Haupt; Ke Xu; Kevin Dooley; Su Chul Jang, PhD; Bryan Choi; Adam Boutin; Christine McCoy; Scott Estes; Kyriakos Economides; Sriram Sathyanarayanan; Nuruddeen Lewis, PhD;	Novel Single-Agent Immunotherapies	Cytokine; Immune adjuvant; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P786	Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab versus atezolizumab for second-line (2L) locally advanced/metastatic urothelial carcinoma (mUC)	Dave Gelb; Yichen Zhong, PhD; Rodolfo Fleury Perini; James Luke Godwin; Yizhen Lai; Stella Arndorfer; Maria Lorenzi, MSc; Haojie Li; Dave Gelb;	Novel Single-Agent Immunotherapies	Checkpoint blockade
P787	Novel humanized CD3ε mouse model for evaluation of bi-specific T-cell engager antibodies	Xiaofei Zhou; Quinn Li; Dirui Li; Rui Huang; Yuelei Shen;	Novel Single-Agent Immunotherapies	Adoptive immunotherapy; Antibody; T cell
P788	Development of ADG116, a novel antagonist anti-CTLA-4 human antibody for cancer immunotherapy	Guizhong Liu, PhD; Felix Fangyong Du; Kristine She; Peter Luo;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Costimulation; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs)
P789	Vaccination of high-risk neuroblastoma patients with anti-id antibody ganglidiomab to maintain protective immunity after passive immunotherapy with anti-GD2 antibody ch14.18/CHO	Hans Loibner, PhD; Holger N. Lode, MD, PhD; Nikolai Siebert, PhD; Sascha Troschke-Meurer, BS; Oliver Mutschlechner; Holger N. Lode, MD, PhD;	Novel Single-Agent Immunotherapies	Antibody; Immune adjuvant; Pediatric tumors; Tumor antigens; Vaccine
P790	The anti-tumor activity of an anti-CD39 antibody (ES002) in a multiple myeloma model is dependent on NK cells	Yangsheng Qiu; Hongtao Lu, PhD; Qinglin Du, PhD; Meiling Sun; Rui Gao, PhD; Huimin Kong; Roumei Xing; Yufei Shi; Mengying Xu; Zhihao Wu, PhD; Hongtao Lu, PhD;	Novel Single-Agent Immunotherapies	Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Immune suppression; Myeloid cells; NK/NK T cell; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P791	Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)	Andy MacKinnon, PhD; Deepthi Bhupathi, MS; Jason Chen; Rosalyn Dang; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Sandra Spurlock; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD;	Novel Single-Agent Immunotherapies	Immune suppression; Myeloid cells; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment
P792	A GUCY2C-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors	Divya Mathur, PhD; Adam Root; Bozena Bugaj-Gaweda; Xingzhi Tan; Wei Fang; Stephanie Bisulco; Jonathon Golas; Jessica Kearney; Erik Upeslacis; Johnny Yao; Edward Rosfjord; Chad Stevens; Lindsay King; Jatin Narula; Kerry Kelleher; Cynthia Rohde; Lioudmila Tchistiakova; Anhco Nguyen; Puja Sapra, PhD;	Novel Single-Agent Immunotherapies	Angiogenesis; Antibody; Biomarkers; Checkpoint blockade; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment
P793	ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Utilizes Multiple Mechanisms to Elicit Potent Anti-Tumor Immunity Superior to Checkpoint Blockade Alone	Mark F. Maurer, BS; Chelsea J. Gudgeon, BS; Katherine E. Lewis, PhD; Sherri Mudri, BS; Stacey R. Dillon, PhD; Martin Wolfson, BS; Steven D. Levin, PhD; Kristine M. Swiderek, PhD; Stanford Peng, MD, PhD;	Novel Single-Agent Immunotherapies	Antigen presenting cells; Checkpoint blockade; Coinhibition; Costimulation; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs)
P794	A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism	Sailaja Battula, PhD; Punit Upadhyaya; Marianna Kleyman; Jessica Kublin; Eric Haines, PhD; Jun Ma; Elizabeth M. Repash; Tom L. Stephen; Julia Kristensson; Liuhong Chen; Kristen E. Hurov; Johanna lahdenranta; Kevin McDonnell, PhD; Nicholas Keen;	Novel Single-Agent Immunotherapies	Costimulation; Cytokine; Myeloid cells; NK/NK T cell; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment
P795	Anti-MUC1 monoclonal antibodies derived from the first non-viral prophylactic cancer vaccine clinical trial can target cancer cells and facilitate their immune-mediated elimination	Michelle L. McKeague, PhD; Jason Lohmueller, PhD; Eric Ricci; William Lu; Olivera J. Finn, PhD;	Novel Single-Agent Immunotherapies	Antibody; NK/NK T cell; Vaccine
P797	Novel dual A2A/A2B receptor antagonist reverses adenosine-mediated immune suppression - in vitro and in vivo characterization.	Michal Galezowski; Paulina Wegrzyn; Aneta Bobowska; Katarzyna Dziedzic; Magdalena Bonkowska; Karolina Grycuk; Joanna Szeremeta-Spisak; Marcin Nowogródzki; Grzegorz Satala; Alicja Obara; Iwona Lozinska-Raj; Przemyslaw Wyrebek; Marcelina Dudek; Anita Janiga; Jacek Reus; Marek Wronowski; Magdalena Zastawna; Grzegorz Statkiewicz; Maciej Rogacki; Mateusz Swirski; Jakub Woyciechowski; Kinga Michalik; Agnieszka Adamus; Karolina Wiatrowska; Natalia Literska; Aniela Golas; Olga Haberkiewicz; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Mateusz Nowak;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Immune suppression; Inflammation; Metabolism; Tumor evasion; Tumor microenvironment
P798	Think Globally Act Locally: Biodistribution of BETA-PRIME, a Replication-Competent Type 5 Adenovirus Enhanced with a Trap for the Immunosuppressive Cytokine, TGF-Beta	Christopher Larson, MD PhD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD;	Novel Single-Agent Immunotherapies	Immune adjuvant; Immune suppression; Regulatory T cell (Treg cell); T cell
P799	Innate leukocyte chemoattractant chemerin is an intrinsic tumor suppressor in prostate cancer	Zhongping Xu, PhD; Woo Jae Shin, BA; Kevin Kim; Brian Zabel, PhD; Russell Pachynski, MD;	Novel Single-Agent Immunotherapies	Chemokine; Solid tumors; Tumor infiltrating lymphocytes (TILs)
P800	Development of PY314, a monoclonal antibody that selectively depletes tumor-associated macrophages, for the treatment of solid tumors	Mikhail Binnewies; Joshua L. Pollack; Venkataraman Sriram, PhD; Erick Lu; Nadine Jahchan; Xiaoyan Du; Aritra Pal; Evan Greger; Kevin Baker; Michel Streuli, PhD; Len Reyno; Venkataraman Sriram;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment; Tumor stroma
P801	Development of the first in class immunotherapy targeting immuno-suppressive δ1 containing γδ T cells for the treatment of pancreatic ductal adenocarcinoma and other solid tumors	Tanya Panchenko, PhD; Wei Wang; Eric Denbaum; Takamitsu Hattori; Akiko Koide, PhD; Aleksandra Filipovic, MD, PhD; George Miller; Tanya Panchenko, PhD; Shohei Koide;	Novel Single-Agent Immunotherapies	Antibody; Immune suppression; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs)
P802	Single cell Immuno- and Cancer Marker Profiling of Non-Small Cell Lung Cancer Tissue: Checkpoint Marker Expression on CD103+, CD4+ T-cells Correlates with Circulating Tumor Enumeration	Kaylan Handique, PhD; Bruce Patterson, BS, MD; Lianne McLean, BA; Bruce Patterson, MD; Will Chow, PhD; Priya Gogoi, PhD; Vishal Sharma, PhD;	Novel Single-Agent Immunotherapies	Adoptive immunotherapy; B cell; Biomarkers; Gene expression; Immune monitoring; NK/NK T cell; Proteomics; T cell; T cell lineages; Targeted therapy
P803	CUE-101, a novel HPV16 E7:pMHC:IL-2:Fc fusion protein, enhances tumor antigen specific T cell activation for the treatment of HPV16-driven malignancies	Steven N. Quayle, PhD; Natasha Girgis, PhD; Dharma Raj Thapa; Zohra Merazga, M.S.; Miguel Moreta; Sandrine Hulot, PhD; Alyssa Nelson, BS.; Lauren Kraemer, BS.; Dominic Beal, PhD; Mark Haydock, BS.; Luke Witt, BS.; Jessica Ryabin, BS.; Jonathan Soriano, MSc; Emily Spaulding, PhD; John F. Ross, PhD; Rodolfo Chaparro, PhD; Ronald Seidel, PhD; Anish Suri, PhD; Saso Cemerski; Kenneth J. Pienta, MD; Mary C. Simcox, PhD;	Novel Single-Agent Immunotherapies	Costimulation; Cytokine; T cell; Vaccine
P804	In vivo efficacy of a PD-L1 targeted Engineered Toxin Body (ETB) comprised of direct cytotoxicity and T-cell mediated tumor targeting	Brigitte Brieschke, BS; Sara LeMar; Joseph D. Dekker, PhD; Garrett Cornelison; Asis Sarkar; Garrett L. Robinson; Jay Zhao, PhD; Aimee Iberg, PhD; Jack P. Higgins, PhD; Hilario J. Ramos, PhD; Erin K. Willert, PhD;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Solid tumors; T cell; Targeted therapy
P805	SRF388, a first-in-class, fully human monoclonal antibody targeting IL 27, blocks the immunoregulatory effects of IL-27 in immune cells and demonstrates preclinical in vivo antitumor activity	Matthew P. Rausch, PhD; Jing Hua; Devapregasan Moodley; Kerry F. White; Katherine H. Walsh; Christine E. Miller; Jamie Strand; Pamela Holland, PhD; Vito J. Palombella, PhD; Jonathan A. Hill, PhD;	Novel Single-Agent Immunotherapies	Antibody; Cytokine; Immune suppression; T cell
P806	Structural implications for GITR agonism in immunotherapies	Hamsell M. Alvarez, PhD; Bryan M. Rogers, MSc; Sarah Chan; Lance Bigelow; Samuel Cichanowicz; Marc Lake; Russell Judge; Ramesh Iyer; Kenton Longenecker;	Novel Single-Agent Immunotherapies	Antibody; Costimulation; Immune adjuvant; T cell
P807	Characterization of anti-tumor immune responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in spontaneous Osteosarcoma	Aish Sathyanarayan; Kelly Makielski, DVM, MS, DACVIM; Aishwarya Sathyanarayan, PhD; Shruthi Naik, PhD; Jaime F. Modiano, VMD, PhD; Stephen J. Russell, MD, PhD; Michael Henson, DVM, PhD; Kathleen Stuebner; Flaviu Alexandru Tabaran; Gerard O; Andrea Eckert; Donna Groschen; Lauren Mills, PhD; Milcah Scott, BS; Aaron L. Sarver, PhD; Michael A. Farrar; Ingrid Cornax, PhD;	Novel Single-Agent Immunotherapies	Cytokine; Immune monitoring; Solid tumors
P809	Preclinical Development of a Novel, Allogeneic, OX40L-Secreting, Therapeutic Cancer Vaccine for use in Combination with a gp96-Secreting Vaccine for Solid Tumors	Matthew M. Seavey, PhD; Jason Rose, MS; Patrick Dillon, PhD; Jayalakshmi Miriyala, MS; Vikas Tahiliani, PhD; Jeff Hutchins, PhD;	Novel Single-Agent Immunotherapies	Immune adjuvant; Tumor antigens; Vaccine
P810	An engineered bi-function fusion protein (CD86-Fc-NKG2a) to reverse NK cell tolerance of malignant cells	Casey W. Shuptrine, PhD; Taylor H. Schreiber, MD, PhD;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Costimulation; Immune tolerance; NK/NK T cell; Tumor evasion; Tumor microenvironment
P811	Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors	Adrian Pelin; Mike Huh, PhD; Matthew Tang, PhD; Fabrice Le Boeuf, PhD; Brian Keller; Jessie Duong; Katherine Clark-Knowles, PhD; Victoria A. Jennings, PhD; Julia Petryk; Alan A. Melcher; Mathieu Crupi, PhD; Ragunath Singaravelu, PhD; Larissa Pikor, PhD; Caroline Breitbach, PhD; Steven H. Bernstein, MD; Michael Burgess, MD, PhD; John Bell, PhD;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Chemokine; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P812	Development of PY159, a monoclonal antibody that repolarizes tumor-associated inhibitory myeloid cells, for the treatment of solid tumors	Michel Streuli, PhD; Linda Liang; Chris Chan; Michel Streuli, PhD; Venkataraman Sriram, PhD; Erick Lu; Joshua L. Pollack; Mikhail Binnewies; Xiaoyan Du; Aritra Pal; Vladi Juric; Evan Greger; Kevin Baker; Len Reyno;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; Granulocyte; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor evasion; Tumor microenvironment
P813	TAS0313, a novel cocktail vaccine of multivalent HLA-A2-, A24- and A3 superfamily-restricted epitopes, demonstrates a synergistic antitumor effect with anti-PD-1 antibody	Yuki Tanaka, MS; Hiroshi Wada, MS; Risa Goto; Toshihiro Osada; Keisuke Yamamura; Satoshi Fukaya; Kazuhisa Minamiguchi; Koichi Ikizawa; Teruhiro Utsugi;	Novel Single-Agent Immunotherapies	Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine
P814	Antibody-interferon-gamma fusion protein for the treatment of B-cell lymphomas	Alex Vasuthasawat; Reiko Yamada King; Kham R. Trinh; Neiki Rokni; Sherie L. Morrison, PhD; John M. Timmerman, MD	Novel Single-Agent Immunotherapies	Antibody; Cytokine; Leukemia/Lymphoma; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P815	Targeting multiple immune checkpoint proteins with novel small molecule inhibitors of Sec61-dependent cotranslational translocation	Jennifer A. Whang, PhD; Janet L. Anderl; Andrea Fan; Christopher J. Kirk; Eric Lowe; Dustin McMinn; Beatriz Millare; Meera Rao; Jack Taunton, PhD;	Novel Single-Agent Immunotherapies	Checkpoint blockade; T cell; Tumor microenvironment
P816	DRP-104 Induces Durable Responses In Vivo by Inhibiting Tumor Glutamine Addiction, Remodeling the Tumor Microenvironment and Stimulating Both the Innate & Adaptive Immune Systems	Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD;	Novel Single-Agent Immunotherapies	Cytokine; Monocyte/Macrophage; Metabolism; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P817	Potent ERAP1 inhibitors modify the immunopeptidome and generate novel neoantigens	Jamie Ware; Kris Clark; Carmen Tong; Jason Shiers; Elisa Lori; Emma Reeves; Henry Leonard; Alihussein Remtulla; Nicola Ternette; Edd James, PhD; Martin Quibell; Lesley Young, PhD; Peter I. Joyce;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Neoantigens; NK/NK T cell; T cell
P818	EGFR Exon-20 Insertion-based Neoantigen Stimulated Effective T-cell Immunity against Non-Small Cell Lung Cancer	Jinpu Yu; Dandan Liu;	Novel Single-Agent Immunotherapies	Neoantigens; Tumor antigens
P819	Regulation of isatuximab-mediated antibody-dependent cellular cytotoxicity of multiple myeloma cells: Rationale for combining isatuximab with anti-PD-1 / anti-TGFβ to enhance anti-myeloma activity	Anlai Wang; Zhili Song; Guang Yang; Rita M. Greco; Joachim Theilhaber; Elvis Shehu; Beatriz Ospina; Fangxian Sun; Yu-Tzu Tai; Kenneth C. Anderson, MD; Chen Zhu; Marielle Chiron, PhD; Francisco J. Adrián;	Novel Single-Agent Immunotherapies	Antibody; Checkpoint blockade; NK/NK T cell; Targeted therapy